Akte Therapeutics Revenue
Biotechnology Research • 
Sydney, New South Wales, Australia • 1-10 Employees
$
Akte Therapeutics revenue & valuation
| Annual revenue | $171,110 |
| Revenue per employee | $86,000 |
| Estimated valuation?This valuation is estimated based on industry average for the Biotechnology Research industry and current estimated revenues | $547,552 |
| Total funding | No funding |
Key Contact at Akte Therapeutics
David Butler
Member Board of Directors
Company overview
| Headquarters | Sydney, New South Wales, Australia |
| NAICS | 541714 |
| Founded | 2023 |
| Employees | 1-10 |
About Akte Therapeutics
Akte Therapeutics is developing epigenetic therapies to boost protein production to halt/reverse monogenic diseases. Our platform overcomes the limitations of existing therapeutic approaches to provide treatments for patients in need.
Employees by Management Level
Total employees: 1-10
Seniority
Employees
Director
Funding Data
Akte Therapeutics has never raised funding before.
Korea, Republic of
South Africa
United Kingdom
Frequently asked questions
Akte Therapeutics is located in Sydney, New South Wales, AU.
Akte Therapeutics generates an estimated annual revenue of $171,110. This revenue figure reflects the company's market position and business performance in its industry.
Akte Therapeutics has an estimated valuation of $547,552. This valuation is calculated based on industry-standard revenue multiples and reflects the company's growth potential and market positioning.
Akte Therapeutics was founded in 2023, making it 3 years old. The company has established itself as a significant player in its industry over this time.
Akte Therapeutics has approximately 1-10 employees. The company continues to grow its workforce to support its business operations and expansion.
4.8
40,000 users
